Should we increase GFR with bardoxolone in Alport Syndrome?
Bardoxolone methyl is a semi-synthetic oleanane triterpenoid and is thought to act by promoting the resolution of inflammation via activation of nuclear factor erythroid 2–related factor (Nrf-2) and inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB).
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Published: |
American Society of Nephrology
2018
|